894 related articles for article (PubMed ID: 12872347)
21. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients.
Chan KC; Leung SF; Yeung SW; Chan AT; Lo YM
Clin Cancer Res; 2008 Aug; 14(15):4809-13. PubMed ID: 18676752
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study.
Wei WI; Yuen AP; Ng RW; Ho WK; Kwong DL; Sham JS
Head Neck; 2004 Oct; 26(10):878-83. PubMed ID: 15390201
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
24. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma.
Tong JH; Tsang RK; Lo KW; Woo JK; Kwong J; Chan MW; Chang AR; van Hasselt CA; Huang DP; To KF
Clin Cancer Res; 2002 Aug; 8(8):2612-9. PubMed ID: 12171892
[TBL] [Abstract][Full Text] [Related]
25. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.
Lo YM; Chan LY; Chan AT; Leung SF; Lo KW; Zhang J; Lee JC; Hjelm NM; Johnson PJ; Huang DP
Cancer Res; 1999 Nov; 59(21):5452-5. PubMed ID: 10554016
[TBL] [Abstract][Full Text] [Related]
26. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.
Chua DT; Wei WI; Sham JS; Cheng AC; Au G
Head Neck; 2003 Jul; 25(7):585-94. PubMed ID: 12808662
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type.
Bortolin MT; Pratesi C; Dolcetti R; Bidoli E; Vaccher E; Zanussi S; Tedeschi R; De Paoli P
Cancer Lett; 2006 Feb; 233(2):247-54. PubMed ID: 15907367
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma.
Mutirangura A; Pornthanakasem W; Theamboonlers A; Sriuranpong V; Lertsanguansinchi P; Yenrudi S; Voravud N; Supiyaphun P; Poovorawan Y
Clin Cancer Res; 1998 Mar; 4(3):665-9. PubMed ID: 9533535
[TBL] [Abstract][Full Text] [Related]
30. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
31. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.
An X; Wang FH; Ding PR; Deng L; Jiang WQ; Zhang L; Shao JY; Li YH
Cancer; 2011 Aug; 117(16):3750-7. PubMed ID: 21319149
[TBL] [Abstract][Full Text] [Related]
32. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA.
Lo YM; Chan AT; Chan LY; Leung SF; Lam CW; Huang DP; Johnson PJ
Cancer Res; 2000 Dec; 60(24):6878-81. PubMed ID: 11156384
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
Chan AT; Ma BB; Lo YM; Leung SF; Kwan WH; Hui EP; Mok TS; Kam M; Chan LS; Chiu SK; Yu KH; Cheung KY; Lai K; Lai M; Mo F; Yeo W; King A; Johnson PJ; Teo PM; Zee B
J Clin Oncol; 2004 Aug; 22(15):3053-60. PubMed ID: 15284255
[TBL] [Abstract][Full Text] [Related]
34. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.
Lei KI; Chan LY; Chan WY; Johnson PJ; Lo YM
Clin Cancer Res; 2002 Jan; 8(1):29-34. PubMed ID: 11801537
[TBL] [Abstract][Full Text] [Related]
36. [Correlation between the kinetics of plasma EBV DNA levels and clinical response during treatment in patients with nasopharyngeal carcinoma].
Peng PJ; Zhao C; Liao H; Wang FQ; Zhang L
Ai Zheng; 2002 Aug; 21(8):817-22. PubMed ID: 12478884
[TBL] [Abstract][Full Text] [Related]
37. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
Ling W; Cao SM; Huang QH; Li YH; Deng MQ
Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
[TBL] [Abstract][Full Text] [Related]
39. Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate?
Lin JC; Liang WM; Jan JS; Jiang RS; Lin AC
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):156-64. PubMed ID: 15337551
[TBL] [Abstract][Full Text] [Related]
40. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes.
Chang KP; Hao SP; Chang JH; Wu CC; Tsang NM; Lee YS; Hsu CL; Ueng SH; Liu SC; Liu YL; Wei PC; Liang Y; Chang YS; Yu JS
Clin Cancer Res; 2008 Nov; 14(21):6979-87. PubMed ID: 18980993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
